We are a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. Our product candidates are based on proprietary polymeric nanoparticles called ACCURINS® , which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS® have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities. We are developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators:
![Dnib Unwind logo](https://files.capedge.com/424B5/0001193125-15-034338/g865669g80l00.jpg)
Company profile
Ticker
BINDQ
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BIND Biosciences Inc, BIND Biosciences, Inc, BIND Therapeutics, Inc
SEC CIK
Corporate docs
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
25 Nov 19
8-K
Regulation FD Disclosure
26 Apr 18
8-K
Regulation FD Disclosure
12 Feb 18
8-K
Regulation FD Disclosure
26 Sep 17
8-K
Regulation FD Disclosure
24 Apr 17
8-K
Other Events
8 Feb 17
15-12B
Securities registration termination
30 Jan 17
8-K
Other Events
21 Dec 16
8-K
Other Events
29 Nov 16
8-K
Other Events
2 Nov 16
Latest ownership filings
SC 13G/A
Dnib Unwind, Inc.
13 Feb 17
SC 13G/A
Dnib Unwind, Inc.
18 Jan 17
4
DANIEL LYNCH
30 Aug 16
4
ROBERT LANGER
30 Aug 16
4
Eric K Rowinsky
30 Aug 16
4
PETER BARTON HUTT
30 Aug 16
4
Charles A Rowland Jr
30 Aug 16
4
ARTHUR TZIANABOS
30 Aug 16
3
GEOFFREY L BERMAN
8 Aug 16
SC 13D/A
Dnib Unwind, Inc.
4 Aug 16
Institutional ownership, Q3 2019
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|